Is Novavax stock a sell after its second-quarter disappointment led to a guidance cut? NVAX stock ranks low among biotechs.
Despite being the first protein-based COVID-19 vaccine in many markets, Novavax's (NVAX) delayed product launch severely affected the company's prospects.
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.